[{"id":"6b3f889b-f740-4f3b-8cf4-23be6228dabd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684108","created_at":"2021-01-19T20:47:15.713Z","updated_at":"2024-07-02T16:35:12.449Z","phase":"Phase 1","brief_title":"SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies","source_id_and_acronym":"NCT04684108","lead_sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","biomarkers":" CD38","pipe":" | ","alterations":" CD38 expression","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SG301 IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-28"}]